Nvidia (NASDAQ: NVDA) has announced a strategic partnership with Eli Lilly to establish an AI co-innovation lab, with plans to invest up to $1 billion over five years. This collaboration aims to leverage Nvidia’s AI technology to expedite drug research and development, addressing the intersection of healthcare and artificial intelligence, as highlighted by CEO Jensen Huang.
As of its latest financial filings, Nvidia holds a stake in Generate Biomedicines (NASDAQ: GENB), valued at approximately $10.4 million for over 833,000 shares. Generate Biomedicines focuses on using AI and machine learning for drug development, with current Phase 3 trials underway for GB-0895, an asthma treatment designed to reduce administration frequency from once a month to just twice a year.
Nvidia’s market capitalization is $4.9 trillion, positioning it to significantly impact the healthcare sector through AI and machine learning innovations, potentially revolutionizing drug discovery and clinical trials.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
